Replimune Group Inc. (REPL)
REPL trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | REPL on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2018 |
| SEC CIK | 0001737953 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "As described in the Company's Annual Report on Form 10-K for the year ended March 31, 2026, substantial doubt existed about the Company's ability to continue as a going concern." | 10-Q 2026-10-28 |
| Cash and burn | $307.8M cash; operating cash flow -$61.4M a quarter. | Report 2026-09-30 |
| Shares outstanding | 94,800,404 (2026-10-31); 78,443,334 a year earlier; 59,059,343 three years earlier. | Cover page 2026-10-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-08-10 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, Florham Park, New Jersey, United States | PCAOB Form AP 2026-07-28 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $1.9M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2027 2026-09-30 | Not filed | -$57.1M | -$47.7M | $307.8M | $99.8M | Needs four quarters | 10-Q 2026-10-28 |
| Q1 2027 2026-06-30 | Not filed | -$69.8M | -$75.7M | $185.4M | $84.1M | Needs four quarters | 10-Q 2026-10-28 |
| Q4 2026 2026-03-31 | Not filed | -$73.2M | -$56.2M | $209.0M | $83.3M | Needs four quarters | 10-K 2026-06-29 |
| Q3 2026 2025-12-31 | Not filed | -$70.9M | -$66.0M | $123.0M | $47.6M | Needs four quarters | 10-Q 2026-02-03 |
| Q2 2026 2025-09-30 | Not filed | -$83.1M | -$81.2M | $102.3M | $47.2M | Needs four quarters | 10-Q 2026-10-28 |
| Q1 2026 2025-06-30 | Not filed | -$86.7M | -$77.0M | $97.4M | $46.8M | Needs four quarters | 10-Q 2026-10-28 |
| Q4 2025 2025-03-31 | Not filed | -$74.1M | -$53.7M | $111.1M | $46.4M | Needs four quarters | 10-K 2026-06-29 |
| Q3 2025 2024-12-31 | Not filed | -$66.3M | -$50.7M | $172.2M | $46.0M | Needs four quarters | 10-Q 2026-02-03 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2026-08-14 |
| Latest annual report | 10-K | 2026-06-29 |
| Latest quarterly / interim FORM 10-Q/A | 10-Q/A | 2026-11-06 |
| Latest current report FORM 8-K | 8-K | 2026-10-28 |
| Latest proxy | DEFA14A | 2026-07-29 |
Source: SEC EDGAR submissions feed, 663 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +1.2% |
| 1 month | +80.8% |
| 3 months | +44.1% |
| Year to date | +125.2% |
| 1 year | +143.8% |
| From 52-week high | -6.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| BCRX | BioCryst Pharmaceuticals Inc. | $7.45 | -2.10% | $1.9B |
| BEAM | Beam Therapeutics Inc. | $20.94 | -8.28% | $2.2B |
| MAZE | Maze Therapeutics Inc. | $33.90 | -1.25% | $1.9B |
| COAG | Hemab Therapeutics Holdings Inc. | $39.05 | -4.42% | $1.8B |
| RXRX | Recursion Pharmaceuticals Inc. | $2.90 | -8.79% | $1.8B |
| WWB | Windward Bio Group AG Common Shares | $30.04 | +5.40% | $1.7B |
| ALVO | Alvotech | $4.41 | +5.13% | $1.7B |
| VIR | Vir Biotechnology Inc. | $9.58 | -3.82% | $1.6B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier